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Patients undergoing aortic surgery or other
major surgical procedures frequently require blood
product replacement during or after the operation.
Methods that have been established in an effort to
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Objective: Because of allogenic red blood cell (RBC) availability and infection problems,
novel alternatives, including hemoglobin-based oxygen-carrying solutions (HBOC), are
being explored to minimize the perioperative requirement of RBC transfusions. This
study evaluated HBOC-201, a room-temperature stable, polymerized, bovine-HBOC, as
a substitute for allogenic RBC transfusion in patients undergoing elective infrarenal aor-
tic operations.
Methods: In a single blind, multicenter trial, 72 patients were prospectively randomized
two-to-one to HBOC (n = 48) or allogenic RBC (n = 24) at the time of the first trans-
fusion decision, either during or after elective infrarenal aortic reconstruction. Patients
randomized to the HBOC group received 60 g of HBOC for the initial transfusion and
had the option to receive three more doses (30 g each) within 96 hours. In this group,
any further blood requirement was met with allogenic RBCs. Patients randomized to the
allogenic RBC group received only standard RBC transfusions. The efficacy analysis was
a means of assessing the ability of HBOC to eliminate the requirement for any allogenic
RBC transfusions from the time of randomization through 28 days. Safety was evaluat-
ed by means of standard clinical trial methods.
Results: The two treatment groups were comparable for all baseline characteristics.
Although all patients in the allogenic RBC group required at least one allogenic RBC
transfusion, 13 of 48 patients (27%; 95% CI, 15% to 42%) in the HBOC group did not
require any allogenic RBC transfusions. The only significant changes documented were
a 15% increase in mean arterial pressure and a three-fold peak increase in serum urea
nitrogen concentration after HBOC. The complications were similar in both groups,
with no allergic reactions. There were two perioperative deaths (8%) in the allogenic
RBC group and three perioperative deaths (6%) in the HBOC group (P = 1.0). 
Conclusion: HBOC significantly eliminated the need for any allogenic RBC transfusion
in 27% of patients undergoing infrarenal aortic reconstruction, but did not reduce the
median allogenic RBC requirement. HBOC transfusion was well tolerated and did not
influence morbidity or mortality rates. (J Vasc Surg 2000;31:299-308.)
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decrease the transfusion requirement of allogenic
blood products involve autologous whole blood pre-
donation, intraoperative hemodilution, and intraop-
erative autotransfusion.1 Added benefits of avoiding
allogenic red blood cell (RBC) transfusions include
reducing incompatibility reactions, the transmission
of infectious agents, immunomodulation, and the
demand on blood supply.2 However, despite these
efforts in blood conservation, allogenic blood trans-
fusion is still frequently necessary during aortic
surgery.
Unless the patient has a coagulation abnormality
or a massive intraoperative blood loss, RBC replace-
ment is the primary transfusion requirement for
elective infrarenal aortic surgery. Preexisting anemia,
surgical blood loss, and hemodilution may lead to
acute intraoperative or postoperative oxygen trans-
port deficits that require allogenic RBC replace-
ment.3 These allogenic RBC transfusions provide a
temporary oxygen transport bridge until endoge-
nous RBC mass or physiologic compensatory mech-
anisms restore oxygen-carrying capacity. Because the
principle deficit restored by allogenic RBC replace-
ment is limited to the oxygen-carrying capacity of
the blood, hemoglobin-based oxygen-carrying solu-
tions (HBOCs) are potential alternatives for provid-
ing a transient oxygen transport bridge during this
acute and transient perioperative anemia.4
This multicenter, randomized study was designed
to evaluate one of the blood substitutes, HBOC-201
(Hemopure, Biopure; Cambridge, Mass), as a safe
and effective alternative for allogenic RBC transfu-
sion for blood loss associated with infrarenal aortic
surgery.
METHODS
Objectives. A multicenter (eight sites), random-
ized, single-blind (to the patient), parallel-group study
was conducted in patients undergoing infrarenal
abdominal aortic reconstruction for aneurysmal or
occlusive disease. Patients were randomized to receive
either HBOC or allogenic RBCs. The study objectives
were to determine the impact of HBOC use on the
allogenic RBC transfusion requirement and to deter-
mine the safety of HBOC treatment in these patients.
The primary efficacy end point was the determi-
nation of the proportion of patients within the
HBOC group for whom allogenic RBC use was
eliminated for the perioperative period of 28 days.
For this end point, the patient’s oxygen-carrying
capacity requirements had to be satisfied by the
administration of HBOC alone, without an allo-
genic RBC transfusion. The secondary efficacy end
point was the determination of the difference in the
median number of allogenic RBC units transfused
between the two treatment groups during the study.
Additional comparisons included patient hemody-
namic, laboratory, and other physiologic parameters,
and hospital length-of-stay in the two treatment
groups. 
Materials. The HBOC used in this study,
HBOC-201 (Hemopure, Biopure), is a glutaralde-
hyde-polymerized hemoglobin extracted from
bovine RBCs (Table I) and has been evaluated in
more than 400 humans. This HBOC has a plasma
half-life of approximately 24 hours and is not known
to be associated with hemolytic reactions or the
transmission of infectious agents.5 This HBOC does
not require 2,3 diphosphoglycerate (2,3-DPG) as a
negative allosteric modifier to enhance oxygen
release, as does human hemoglobin.6
HBOC was supplied in sterile plastic bags, did
not require reconstitution, and was stored at room
temperature. Because HBOC contains no RBC
membrane antigens, there was no need to cross-
match HBOC to the patient’s blood. The protocol
for HBOC administration for the initial transfusion
was 60 g in 500 mL (modified lactated Ringers),
and, when indicated, for the three subsequent trans-
fusions, the doses were 30 g each in 250 mL.
Allogenic RBC units, typically containing 60 to 70 g
of hemoglobin in approximately 250 mL, were
stored and administered by using standard tech-
niques. Because the transfusion products (RBC and
HBOC) are easily distinguished, specific protocols
were established to provide patient blinding by
ensuring that tubing and products were shielded
from their view.
Informed consent. This study was conducted in
compliance with the institutional review board reg-
ulations in the Code of Federal Regulations (21
CFR, Part 56) and the informed consent regulations
(21 CFR, Part 50) and in compliance with the ethi-
cal principles in the Declaration of Helsinki. Each
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Table I. Characteristics and specifications of the
hemoglobin-based oxygen-carrying solution,
HBOC-201
Average molecular weight 240 kd
Storage requirements Room temperature (2 to 37°C)
Colloid osmotic pressure 17 mm Hg
Osmolarity 290 to 310 mOsm/kg
Viscosity (37°C) 1.3cP
Reconstitution None required
Administration Peripheral or central vein
pH 7.6 to 7.9
P50 38 mm Hg
Hemoglobin concentration 13 ± 1 g/dL
Endotoxin concentration < 0.5 EU/mL
Phospholipid concentration < 0.1 µg/mL
EU, Endotoxin units.
participating institution obtained the approval of its
respective institutional review board. The eligible
patients provided informed consent before surgery. 
Patient population. Male and female patients,
30 to 80 years of age, who were undergoing abdom-
inal aortic reconstruction from December 1996 to
July 1998 were candidates for the study. Eligibility
criteria also included informed consent and medical
stability (ASA Class II or III). Enrollment also
required that patients meet theses perioperative cri-
teria: (1) the initial transfusion episode occurred in
the interval between the initiation of the operation
and the discharge from the postsurgical intensive
care unit (ICU); (2) the hemoglobin concentration
was 6.5 to 9.0 g/dL or the hematocrit level was 19%
to 27%; (3) all available autologous blood had been
infused; and (4) a transfusion had been prescribed.
Patients undergoing emergency surgery, extended
suprarenal clamping, or planned concomitant renal
or visceral reconstruction were excluded from this
study. Patients were also excluded if they had a cre-
atinine level greater than 2.0 mg/dL, uncontrolled
hypertension, a known left ventricular ejection frac-
tion less than 30%, active infection or sepsis, unsta-
ble medical disease (ASA IV or V classification), or a
history of allergy or intolerance to bovine products.
Study design. With the exception of the inclusion
criteria, the protocol did not dictate subsequent trans-
fusion criteria to participating physicians, but request-
ed them to use clinical criteria. All patients were cross-
matched for allogenic RBCs based on standard prac-
tice. Clinical protocols already in place to minimize
allogenic RBC transfusion, such as autologous predo-
nation, intraoperative autotransfusion, or anticoagula-
tion reversal, were used according to the surgeon’s
routine. In this series, all patients received heparin at
the time of aortic cross-clamping.
The protocol required the first infusion to be in
the operating room or ICU to optimize patient
monitoring. Selection bias resulting from the trans-
fusion product was avoided because patients were
not randomized until after the first transfusion deci-
sion was made. Both physician and patient were
blinded to the assignment group of the patient
before randomization, but only the patient remained
blinded for the remainder of the study. On enroll-
ment, a sealed envelope was opened to assign the
patient to either the HBOC or the allogenic RBC
group. The patients were randomized proportion-
ately two-to-one, HBOC to allogenic RBCs. In this
trial, the transfusion dose was limited for both study
groups. Patients could either receive a maximum of
four doses (150 g) of HBOC or four allogenic RBC
transfusions within 96 hours after the initial transfu-
sion decision. After 96 hours or four transfusions,
whichever occurred first, all subsequent transfusions
in either treatment group consisted of allogenic
RBCs.
Assessments. Patients were initially screened
with baseline laboratory data and physiologic para-
meters to satisfy the inclusion criteria. Blood pres-
sure, heart rate, temperature, complete blood counts,
and clinical chemistries were recorded on postopera-
tive days 1, 2, 3, 4, 5, 8, or at the time of discharge
and at the time of a late follow-up examination, at 4
weeks. Antibody levels to bovine hemoglobin were
drawn before the initial transfusion and at the 4-week
follow-up examination. Additional baseline studies
were performed after the decision was made to give
the patient a transfusion, but before the first infusion.
Hemodynamic measurements and arterial blood gas
data were obtained before and 15 minutes after the
first infusion. Anemia in the HBOC patients was
assessed only by means of plasma hemoglobin con-
centrations, and anemia was assessed in the allogenic
RBC patients by means of either hematocrit or
hemoglobin concentrations. 
Adverse events, defined as clinical problems that
occurred or worsened after treatment with the
HBOC or allogenic transfusion, vital signs, and elec-
trocardiogram results were recorded. The number
and type of all transfusions in the study period were
recorded for all patients. The length of hospital stay
was measured from the end of the vascular surgical
procedure to the day of discharge from the hospital. 
Statistical methods. All enrolled and random-
ized patients who received any amount of treatment
were included in the analysis. Data are presented as
the mean plus or minus SEM. The proportion of
patients within the HBOC group who did not
require allogenic RBC transfusions to the 28-day
follow-up examination was evaluated by calculating
a 95% “exact” CI around the observed proportion
of patients. The numbers of allogenic RBCs trans-
fused are reported as medians and analyzed by
means of the nonparametric Kruskal-Wallis test,
because the data were not normally distributed.
Mortality and complication rates were compared
with the Fisher exact test. Changes in hemodynamic
measurements and laboratory test results were sub-
jected to Wilcoxon tests. A P value of less than .05
was considered significant.
RESULTS
Seventy-two patients were randomized two-to-
one (48 patients in the HBOC group and 24
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patients in the allogenic RBC group) at eight inves-
tigative centers. Demographic and baseline charac-
teristics of patients were similar in both groups
(Table II). Although it was allowed by means of the
protocol, no patients in the study underwent acute
normovolemic hemodilution.
Allogeneic red blood cell use. Thirteen patients
(27%; 95% confidence limits, 15% to 42%) in the
HBOC group received no allogenic blood transfu-
sions by the 28th postoperative day. More than half
these patients (54%) required only the first unit of
HBOC to satisfy their oxygen-carrying capacity. The
median number of allogenic RBC units transfused
was 2.5 (range, 1 to 21) in the RBC group and 2.0
(range, 0 to 23) in the HBOC group (Table III; P
= .9). Three of the 24 patients (13%) in the RBC
group and 12 of the 48 patients (25%) in the HBOC
group received more than five transfusions during
the study (P = .36). 
Twenty-two of the 24 patients (92%) in the RBC
group and 45 of the 48 patients (94%) in the HBOC
group received their first infusion of randomized
treatment on the operative day. Sixteen of the 48
patients (33%) in the HBOC group completed the
full dose of HBOC and also received their first allo-
genic RBC unit on the day of operation. An addi-
tional 10 of the 48 patients (21%) in the HBOC
group received their first allogenic RBC unit on the
first postoperative day. Of the 19 of 48 (40%)
HBOC patients who started their allogenic RBC
requirement after the operative day, 12 patients
(63%) were transfused only 1 (1 of 12) or 2 (11 of
12) units of allogenic RBCs. Six of the 48 patients
(12%) in the HBOC group received their first allo-
genic transfusion after 96 hours, at which time,
according to the protocol, patients were not eligible
to receive additional HBOC.
Patient variables with transfusion. The only
major change in the clinical variables measured
before and after the first treatment was a significant
increase in mean arterial pressure in the HBOC
group, compared with that of the allogenic RBC
group (Table IV; P < .008). However, changes in
mean pulmonary arterial pressure, pulmonary arter-
ial occlusion pressure, cardiac index, and oxygen-
delivery index were similar for the two treatment
groups. The base excess was also significantly greater
in the HBOC group, which may indicate more effi-
cient oxygen release from HBOC than from allo-
genic RBCs, as previously reported.7
As expected, after the infusion, the plasma hemo-
globin concentration increased in the HBOC group,
but not in the RBC group, whereas the hematocrit
level increased in the allogenic RBC group. However,
the hematocrit level decreased after infusion in the
HBOC group, because HBOC is an isoncotic colloid
that expands plasma volume and may produce
hemodilution.8 The mean increase in total hemoglo-
bin concentration after transfusion was less in the
HBOC group, when compared with that of the allo-
genic RBC group. There were no differences between
the hematocrit levels of the HBOC group and the
allogenic RBC group at the time of discharge (32 ±
0.8 vs 31 ± 0.7, P = not significant) or at the 4-week
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Table II. Patient demographic and baseline charac-
teristics*
RBC HBOC 
group group
Characteristic (n = 24) (n = 48) P value
Primary diagnosis of 
abdominal aortic 
aneurysm (%)† 79 81 1.0
Sex (% men) 83.3 79.2 .67
Smoking history 
(% current) 33.3 47.9 .28
Age (years) 70.3 ± 1.8 68.9 ± 1.1 .50
Weight (kg) 74.2 ± 3.0 76.4 ± 2.1 .53
Hemoglobin 
concentration 
(g/dL) 13.6 ± 0.3 13.2 ± 0.3 .40
Hematocrit level (%) 40.8 ± 0.8 39.7 ± 0.8 .37
Patients predonating 
autologous blood 1 2 1.0
Creatinine levels 
(mg/dL) 0.93 ± 0.06 0.92 ± 0.05 .72
Operative time 
(minutes) 225 ± 17 227 ± 11 .50
Cross-clamp time 
(minutes) 74 ± 9 72 ± 5 .50
*Continuous variables are mean plus or minus SEM. Categorical
variables are percentages.
†Remaining patients have diagnosis of occlusive disease.
RBC, Red blood cell; HBOC, hemoglobin-based oxygen-carry-
ing solution.
Table III. Patients who received a transfusion of a
specified number of allogenic RBC units
RBC group HBOC group
Number of units (n = 24) (n = 48)
0 0 (0%) 13 (27%)
1 2 (8%) 2 (4%)
2 10 (42%) 12 (25%)
3 5 (21%) 2 (4%)
4 2 (8%) 5 (10%)
5 2 (8%) 2 (4%)
>5 3 (13%) 12 (25%)
RBC, Red blood cell; HBOC, hemoglobin-based oxygen-carry-
ing solution.
follow-up examination (37 ± 0.9 vs 36 ± 0.5, P = not
significant).
Laboratory variables. For both treatment
groups, the mean values of the maximum increases
from baseline measurements to discharge levels of
serum urea nitrogen, creatinine, lipase, aspartate
aminotransferase, and alanine aminotransferase were
compared (Table V). These variables were selected
because of historical concerns with other HBOC
formulations.4 Considering these variables, only the
serum urea nitrogen level increased significantly in
the HBOC group. Antibody levels of IgE to bovine
hemoglobin were not induced in any patients in this
study. In one patient, who had elevated baseline lev-
els of IgE to bovine hemoglobin, a mild increase in
IgE levels developed, but did not manifest an aller-
gic reaction to HBOC. 
Adverse reactions. Twenty-three patients (96%)
in the RBC group and 42 patients (88%) in the
HBOC group had adverse reactions, which were not
clinically serious. Reactions reported more com-
monly (P < .10) in the RBC group were postural
hypotension, vesiculobullous rash, dyspepsia, keto-
sis, monocytosis, hypesthesia, confusion, and abnor-
mal mentation. The only reaction reported more
commonly (P < .10) in the HBOC group was the
development of a rash. Most of these rashes were
observed to involve the skin underlying removed
adhesives or after skin abrasion and probably repre-
sent transient translocation of HBOC into the skin.
Postoperative complications were reported for
nine of the 24 patients (38%) in the RBC group and
18 of the 48 of patients (38%) in the HBOC group
(Table VI). Among these patients, two of the 24
(8%) in the RBC group and three of the 48 in the
HBOC group (6%) died (P = 1.0). Eight percent of
patients (2 of 24) in the RBC group and 17% of
patients (8 of 48) in the HBOC group had increased
perioperative bleeding (P = .47). The RBC and
HBOC groups had similar lengths of hospital stay
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Table IV. Changes in hemodynamic and blood gas variables before and after first infusion
RBC group HBOC group
(n = 24) (n = 48)
Variable Baseline Change Baseline Change P value
Heart rate (minutes–1) 71 ± 4 –0.8 ± 2.2 74 ± 2 –4.3 ± 1.6 .30
Mean arterial pressure (mm Hg) 74 ± 2 –2.0 ± 2.8 79 ± 2 12.0 ± 2.9 .008
Cardiac index (L/min/m2) 2.89 ± 0.25 0.09 ± 0.31 2.97 ± 0.18 –0.12 ± 0.29 1.0
Oxygen-delivery index (mL/min/m2) 332 ± 25 –32 ± 41 362 ± 24 –5 ± 47 .93
Mean pulmonary artery occlusion pressure 22.2 ± 1.3 1.6 ± 1.2 22.7 ± 1.2 4.2 ± 2.4 .57
(mm Hg)
Pulmonary artery occlusion pressure 15.0 ± 1.2 0.3 ± 1.8 14.8 ± 1.0 –0.5 ± 1.3 .77
(mm Hg)
Temperature (°C) 35.7 ± 0.2 0.04 ± 0.06 35.7 ± 0.1 0.07 ± 0.08 .63
PaO2 (mm Hg) 175 ± 16 6 ± 14 161 ± 12 –3 ± 14 .84
PaCO2 (mm Hg) 38 ± 1 2.0 ± 1.6 39 ± 1 2.6 ± 0.8 .40
pH 7.39 ± 0.01 –0.03 ± 0.01 7.37 ± 0.01 –0.02 ± 0.01 .30
Bicarbonate (mmol/L) 22.4 ± 0.50 –0.7 ± 0.44 22.7 ± 0.31 0.49 ± 0.36 .08
Base excess (mmol/L) –1.7 ± 0.6 –1.6 ± 0.6 –1.5 ± 0.4 0.40 ± 0.4 .02
Arterial oxygen saturation (%) 98.6 ± 0.30 0.09 ± 0.12 98.2 ± 0.25 –0.11 ± 0.35 .89
Total hemoglobin concentration (g/L) 88.7 ± 1.9 9.8 ± 0.3 86.1 ± 2.0 3.3 ± 1.8 .06
Plasma hemoglobin concentration (g/dL) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.15 ± 0.11 .001
Hematocrit level (%) 26.7 ± 0.6 2.7 ± 0.8 26.1 ± 0.6 –1.8 ± 0.6 .001
RBC, Red blood cell; HBOC, hemoglobin-based oxygen-carrying solution.
Table V. Maximal chemistry value increase from baseline to discharge
RBC group HBOC group P value
Serum urea nitrogen level (mg/dL) 6.80 ± 1.91 19.8 ± 4.8 .002
Creatinine level (mg/dL) 0.281 ± 0.066 0.408 ± 0.066 .31
Lipase level (IU/L) 7.4 ± 16.2 82.15 ± 40.8 .19
Aspertate aminotransferase level (IU/L) 50.0 ± 16.1 74.9 ± 24.8 .14
Alanine aminotransferase level (IU/L) 42.1 ± 13.1 46.8 ± 18.3 .38
Values are mean plus or minus SEM.
RBC, Red blood cell; HBOC, hemoglobin-based oxygen-carrying solution.
(median, 8.0 and 8.5 days, respectively; P = .11) and
ICU stay (median, 1.5 and 1.9 days, respectively; P
= .83). Treatment was discontinued for two patients
in each study group because of an adverse event;
however, these patients remained in the study for the
purposes of evaluating safety.
DISCUSSION
This study was designed to determine whether
patients undergoing infrarenal abdominal aortic
surgery who required RBC transfusion could be
treated with HBOC alone. The demographic char-
acteristics were indistinguishable in both study
groups. The administration of HBOC in this study
was demonstrated by means of the primary efficacy
end-point data to eliminate the need for periopera-
tive allogenic RBC transfusions in more than one
fourth of the study patients (27%). Of the 35 HBOC
patients who required allogenic RBCs, 12 patients
(34%) required only 1 or 2 units of allogenic RBCs
to meet their oxygen-carrying capacity require-
ments. Furthermore, an additional 12% of the
patients who received HBOC were given allogenic
RBCs only after the 96-hour post-transfusion time
limit imposed by the study protocol had elapsed and
their eligibility for additional HBOC administration
had expired. The protocol was originally designed to
be a step-wise progression from a previous study of
cardiac surgery patients, in which serial exposures to
HBOC was limited to a total dose of 120 g admin-
istered in 72 hours.9 Current protocols extend the
maximum HBOC dose to 300 g administered in 6
days, in contrast with the 150 g dose in 4 days
allowed in this report.
The overall median number of allogenic RBC
units transfused in the duration of the study was not
significantly different between the two groups, as
demonstrated by means of the secondary efficacy
end-point data. This result differs from that
observed in similar studies with HBOC.9,10 There
are probably several reasons for this apparent dis-
crepancy. It could have resulted from the protocol
limitations restricting the HBOC administration or
because of a greater blood loss, possibly from the use
of HBOC in this patient population, in those
patients randomized to the HBOC group. Thirteen
percent of the patients in the allogenic RBC group
and 25% of the patients in the HBOC group
received more than five allogenic RBC transfusions
during the study period. Although not statistically
different between the two groups, the greater blood
loss in these patients occurred for a variety of rea-
sons, including prolonged ICU stay, gastrointestinal
bleeding, and perioperative bleeding. Although a
transient increase in mean arterial pressure from 74
to 79 mm Hg was noted with the administration of
HBOC in this study, it seems insufficient to explain
the increased blood requirement. Furthermore,
increased bleeding associated with this minimal pres-
sure change has not been observed in other studies
of HBOC.9,10 Although the present investigation
involves a small sample size, it is suggested by means
of these data that HBOC may be most effective in
eliminating the need for urgent transfusion in select-
ed patients, rather than in reducing the total RBC
transfusion requirement in this patient population.
Although HBOC in this study did not reduce the
demand on the available blood supply, it did post-
pone the first RBC transfusion and also allowed
exposure of 27% fewer patients to a potential infec-
tious risk. 
In this study, HBOC was associated with a tran-
sient increase in systemic blood pressure, but the
cardiac index and pulmonary pressures were not
affected. Although extreme blood pressure increases
are potentially detrimental, such small increases in
systemic blood pressure produced by HBOC may be
an advantage for vascular patients, who often require
temporary blood pressure support. Although nitric
oxide scavenging by hemoglobin has been implicat-
ed as a mechanism for this observation, a recent
investigation of several hemoglobin formulations
found that those products exhibiting the greatest
nitric oxide affinity showed the least increase in
blood pressure.11 These results suggest that the dif-
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Table VI. Patients with complications*
RBC group HBOC group
Complication (n = 24) (n = 48)
Stroke 2 (8%) 2 (4%) [1†]
Ventricular arrhythmia 1 (4%) 2 (4%) [1†]
Heart failure 3 (12%) [1†] 1 (2%)
Cardiac, minor 0 2 (4%)
Peripheral ischemia 1 (4%) 1 (2%)
Venous thrombosis 1 (4%) 2 (4%)
Renal insufficiency 1 (4%) 0
Gastrointestinal 1 (4%) 2 (4%)
Pancreatitis 0 1 (2%)
Pneumonia 1 (4%) 3 (6%)
Wound complication 0 1 (2%)
Hemorrhage 1 (4%) [1†] 3 (6%) [1†]
Air embolus 0 1 (2%)
*Patients who had more than one postoperative complication
identified by the investigator are listed under all applicable cate-
gories. No observed difference was statistically significant.
†Number of patients who died as a result of the complication.
RBC, Red blood cell; HBOC, hemoglobin-based oxygen-carry-
ing solution.
ferences in blood pressure increases that were
observed with HBOC solutions were probably not
the result of nitric oxide scavenging reactions. An
alternative physiologic mechanism implicates the
hemoglobin-induced release of the endogenous
vasoconstrictor endothelin-1, which is known to
occur in the presence of diaspirin cross-linked hemo-
globin,12 but has not been associated with the
HBOC used in this study.
These results demonstrated equivalent safety
between the HBOC and the RBC groups, because
the two treatment groups had similar mortality and
complication rates. Renal failure, although a histori-
cal concern with the use of HBOC solutions,4 was
not observed in this trial. Although the maximum
increases in creatinine levels were similar for both
study groups, the maximum increases in serum urea
nitrogen determinations were greater for the HBOC
group. This can be explained because HBOC pro-
vides a high protein load with a higher rate of
turnover because of its short half-life of 24 hours,
compared with transfused RBCs. The effect was
transient, however, because the proportion of
patients with abnormal serum urea nitrogen or cre-
atinine values were indistinguishable for both groups
at late follow-up. Although pancreatitis developed in
one patient in the HBOC group in this study, lipase
levels have been elevated in some patients after an
HBOC exposure.13 In this study, the noted increase
in lipase levels was not associated with symptoms,
except in the one patient. 
Although other investigators have reported peri-
operative mortality rates of approximately 4% for
elective, infrarenal aortic aneurysm repair,14 the
overall mortality rate in this series was 7% (5 of 72
patients), and it was also similar for both study
groups. The higher mortality rate observed in this
trial may reflect selection bias, because it has been
reported that the requirement for transfusion, which
was one of the inclusion criteria for this study, is
associated with increased morbidity and mortality
rates.15,16 No major allergic reactions, such as ana-
phylaxis, urticaria, bronchospasm, or laryngeal
edema, were reported in either group, and only the
development of a rash was observed more common-
ly in the HBOC group. Thus, HBOC appeared to
be safe for administration to patients undergoing
abdominal aortic surgery. 
Despite their appeal, HBOC solutions also pos-
sess limitations. They may produce substantial vol-
ume expansion from colloid effect, which is greater
than that observed with RBC transfusion.5,17
Although HBOC solutions are generally well toler-
ated, some patients with poor cardiac function, espe-
cially those patients with diastolic cardiac dysfunc-
tion, may sustain symptoms of acute volume over-
load. HBOC solutions also have a shorter half-life
than RBC transfusions and, therefore, may require
repeated administration to correct a large oxygen-
carrying deficit. Because enzymes within the RBCs
maintain hemoglobin in a reduced state, methemo-
globinemia development is a concern when the
hemoglobin is free in plasma, as it is with the use of
hemoglobin solutions.18 The presence of HBOC in
the plasma also interferes with some colorimetric
assays used for clinical laboratory testing, such as
those for bilirubin, alkaline phosphatase, and albu-
min, but not those important for perioperative man-
agement, such as electrolytes and renal function.19
Despite these issues, several blood substitutes,
including HBOC-201, are currently in the later
stages of clinical trials and may soon be available for
use in the United States. Other hemoglobin solu-
tions, derived from expired banked human blood
and perflurocarbon emulsions, are currently being
investigated for surgical applications that include
acute normovolemic hemodilution and trauma
resuscitation.20 Data from these and other large tri-
als will further clarify the risks and benefits of these
solutions, compared with those of conventional allo-
genic RBC transfusion.
In summary, HBOC was used to treat perioper-
ative anemia in patients undergoing elective aortic
surgery. All candidates for enrollment in this trial
would have required at least one allogenic RBC unit.
The use of HBOC eliminated the need for any peri-
operative allogenic RBC transfusion in 27% of
patients undergoing aortic surgery. Although the
reduction of total RBC transfusion was not signifi-
cant, HBOC administration delayed RBC transfu-
sion in all patients. HBOC administration was well
tolerated, and it demonstrated the ability to substi-
tute for blood. This room-temperature stable blood
substitute may provide a temporary oxygen trans-
port bridge until endogenous RBC mass can restore
adequate oxygen-carrying capacity, especially when
RBC units are not immediately available but surgery
is urgently required. 
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DISCUSSION
Dr G. Patrick Clagett (Dallas, Texas). Ladies and gen-
tlemen, this is an exciting paper and offers the prospect of
freeing a significant proportion of our patients from allo-
genic blood transfusion. The results parallel those of a
companion study, sponsored by the same company, in car-
diac surgery patients. In that study, a similar proportion of
patients, approximately one third, were spared transfusion.
However, a major difference between the studies is that in
the cardiac surgery study, overall transfusion requirements
were significantly reduced in patients receiving the hemo-
globin solution, whereas in the present study, this was 
not the case. This is disappointing, but not surprising,
given the short half-life of the hemoglobin solutions.
These solutions do provide a temporary oxygen-transport
bridge, but it is a short bridge. 
This leads me to my first question, how do you explain
the similar hematocrit levels at discharge in the two patient
groups? If the blood losses were similar, one would expect
hematocrit levels to be lower in the patients transfused
with hemoglobin solutions in place of red cells. 
Another concern is with patients who have received
hemoglobin solutions, but who still have low hematocrit
levels at the time of discharge. For example, in the case of
a patient who has received hemoglobin solution and is
nearing discharge from the hospital with a hematocrit level
of 20%, what do the authors recommend? 
The vasoconstrictive effects of hemoglobin solutions
may also be problematic. The temporary rise in mean arte-
rial pressure may have been caused by volume expansion
properties; however, concerns about nitric oxide scaveng-
ing and the release of endogenous endothelin-1 with sys-
temic vasoconstriction remain possibilities. A recent mul-
ticenter trial in trauma patients who received a different
hemoglobin solution was halted because excess mortality
was demonstrated by means of an interim analysis. In part,
the increase in mortality was felt to be caused by under-
resuscitation, because the vasoconstrictive effects of the
hemoglobin solution masked underlying volume deficits. I
would like the authors to comment on this possibility in
the present study, particularly in light of the elevated
serum urea nitrogen levels in patients receiving the hemo-
globin solution. 
Adverse effects from vasoconstriction may also be
manifest in coronary ischemia or visceral ischemia. The
patients in the present study were relatively good-risk
patients. There were no ASA Class IV patients. In addi-
tion, only 72 patients were recruited in a 1.5-year period
from eight busy medical centers. This raises the suspicion
that these patients were highly selected, relatively healthy
patients who could tolerate the vasoconstrictive effects of
this drug. What would happen in poorer-risk patients who
have diffuse coronary and vascular disease? 
Finally, I’d like to ask the authors about the risk of dis-
ease transmission, especially bovine spongiform encephal-
opathy. Are we trading the risk of acquired immunodefi-
ciency syndrome for the risk of mad cow disease? 
Thank you.
Dr Glenn M. LaMuraglia. Thank you, Dr Clagett, for
your comments and your insightful questions. 
I’d like to start with the first question, relating to the
similar hematocrit levels at the time of discharge from
the hospital, which were noted in the cardiac patients.
The length of hospital stay for these patients was approx-
imately 8 days, the half-life of the drug is 4 days, and the
patients were not able to receive any drug after the 96-
hour point. So, a number of those patients with the low
hematocrit levels, who were probably getting ready for
discharge from the hospital, were the outliers, the extra
12% of the patients who received the red cells before the
time of discharge from the hospital. Therefore, they were
considered hemoglobin-based oxygen-carrying solution
failures. 
There is also, around the time after surgery, a hemo-
concentration that occurs with the redistribution of fluids
that were given at the time of anesthesia and surgery. And
I think that would, in its own right, to some extent, hemo-
concentrate these patients. These hemoglobin-based oxy-
gen-carrying solutions, because they are iron carrying and
have short half-lives, do provide an iron load to the bone
marrow. And although there is a hematopoietic effect,
which is not dependent on erythropoietin, it hasn’t really
been carefully studied in this particular hemoglobin-based
oxygen-carrying solution; it has been reported in some of
the other hemoglobin solutions. 
It’s difficult to answer your question relating to a
patient with a hematocrit level of 20% at the time of dis-
charge from the hospital. I think that most of those
patients would probably receive red cell transfusions.
However, I think there are some other considerations that
need to come into play: the absolute need of blood, the
symptoms of the patient, and the half-life of these solu-
tions, which is short. However, in one of the trials that’s
presently being conducted with orthopedic patients, some
patients, who are being discharged a lot earlier than our
aortic surgical patients, actually come back and are able to
receive a select number of hemoglobin-based oxygen-car-
rying solutions as outpatients. However, the safety of
repeated doses of these materials needs further evaluation. 
Your question about the vasoconstrictive effect is very
astute. Yes, that large trial of trauma patients was aborted
because of the high mortality that was identified. It was
conducted with a different hemoglobin solution, one that
was a tetrameric stabilized, as opposed to a polymerized,
hemoglobin. And one of the considerations of some of
these biologic effects are related to the size of these mole-
cules. 
For the nitric oxide affinity, there has been no correla-
tion, looking at a number of different hemoglobin-based
oxygen-carrying solutions and their affinity for nitric
oxide, to their vasoconstrictive effect, so it must be by
other mechanisms. The endothelin-1 release that you
mentioned has been shown with that hemoglobin-based
oxygen-carrying solution used in the study that was dis-
continued, but it has not been shown in some of the other
hemoglobin solutions. 
Under-resuscitation is possible, but I think probably
unlikely. I think a lot of the increase in mean arterial pres-
sure may be caused by the large colloid effect that is pre-
sent with this administration. And in our data, although
the serum urea nitrogen level increased, this may be a
large protein load that is quickly turned over and may
cause a transient increase in the serum urea nitrogen lev-
els, and the creatinine level was not similarly affected in
the hemoglobin-based oxygen-carrying solution group. 
I share your observations that this is a highly selected
group, which is necessary for many of these studies to try
to keep the number of patients down. Unfortunately, a lot
of the patients whom we tried to enroll into the study did
not require blood and therefore were not candidates.
However, because every patient who entered this study
did require a blood transfusion, there is data to suggest
that those patients who do require transfusions require
them for a reason; therefore, they may be at higher risk for
the reasons that require them to be transfused, and there-
by they achieve a higher morbidity and mortality. 
I don’t know whether there will be an independent
effect of these solutions on some of the higher Class IV
patients to whom you alluded, but I think it’s something
about which we have to caution ourselves for its adminis-
tration. 
On your question relating to disease transmission, I
concur. I think we have to be cautious and concerned
about potential contamination in any biological material,
no matter how well it’s purified, when it’s administered to
patients. The prions that cause mad cow disease are appar-
ently removed by an accepted process before polymeriza-
tion of this hemoglobin. The company apparently selects
the blood from cows of select US cattle to avoid the pos-
sibility of having prions. 
I’m delighted that Dr Clagett is the person who has
brought up this concern about this transmission: Are we
trading acquired immunodeficiency syndrome for mad
cow disease? Because, in Texas, considering the volume 
of beef that is consumed and cooked rare, I would pre-
sume that we would hear concerns far in advance about
mad cow disease in our cow population before we con-
cern ourselves about contamination of this hemoglobin
solution.
Dr Gary A. Fantini (New York, NY). Congrat-
ulations on a very finely presented study. You commented
on the excess iron load that these patients are receiving.
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This is substrate for bone marrow. Excess free iron in the
circulation can also be damaging for the promoted gener-
ation of oxygen radicals, peroxynitrite formation from
interaction with nitrous oxide, which can produce oxidant
injury. Can you speculate on whether the renal dysfunc-
tion that you noted in these patients may have been caused
by oxidant generation? 
For safety profiling and toxicity information regarding
these hemoglobin-based oxygen-carrying solutions, iron
administration is cumulative and, at certain levels, must be
removed from the body with compounds such as deferox-
amine. Is there some upper limit that these patients can
safely receive? 
Congratulations once again on a very fine presentation.
Dr LaMuraglia. Thank you for your questions. 
With respect to the elevated serum urea nitrogen lev-
els, because it did not occur with a concomitant elevation
of creatinine levels, and these were all transient, it may be
more related to an acute protein load, than actual renal
dysfunction. There were no patients with renal failure in
this group. 
With respect to the iron load, it is given and is actual-
ly provided to the marrow in a much more rapid fashion
than it would be through transfusions of red cells.
However, the amount of hemoglobin in a standard unit of
red cells is approximately 70 to 80 grams. And in these
hemoglobin-based oxygen-carrying solutions, the initial
one that was given was 60 g, followed by a maximum of
three more of 30 g for a total of 150 g. At the present
time, they are looking at the safety of 300 g for a total
dose, and that would come to approximately 4 units of red
cells. So, I think for the iron load, at least the cumulative
iron load, at the present doses that are being tested, it is
not really a significant concern.
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